Patient Considerations in R/R Mantle Cell Lymphoma Treatment: Anita Kumar, MD

This content originally appeared on our sister site, OncLive.

OncLive spoke with Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, about patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma (MCL).

Kumar discussed several patient considerations that should be accounted for at the time of treatment initiation, including age, overall fitness, and existing comorbidities. Patient goals with therapies should also be considered, Kumar added. Some patients prefer to receive well-tolerated therapies to maximize quality of life, whereas others prefer to treat their MCL aggressively with all available options, Kumar said. Moreover, patient preference could determine whether they should be treated in a community setting vs an academic setting, Kumar added.

Other considerations include whether the patient is eligible for CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant, Kumar says. Regarding the latter, donor availability then becomes an additional factor to consider, Kumar concluded.